This site uses cookies to store information on your computer. I'm fine with this Cookie information

Robotic Arm Trials at Glasgow Royal Infirmary

June 04, 2010 11:58 AM

News Image

A state-of-the-art robotic arm for orthopaedic surgery that has the potential to transform the way in which knee joint replacements are conducted in the UK and reduce cost, is to be employed in clinical studies at the NHS Greater Glasgow and Clyde’s Royal Infirmary and the University of Strathclyde.

It is the first time the robotic arm technology pioneered by the MAKO Surgical Corp. will be used outside the U.S. The American firm has joined forces with orthopaedic surgeons from NHS Scotland and leading scientists from the University to establish the multidisciplinary MAKO Centre for Surgical Robotics, which was officially launched today (Thursday 3rd June 2010).

Over the course of the next three years, the Centre at the University’s department of bioengineering, together with the participating surgeons at the NHS, will engage in randomised clinical trials of MAKO’s RIO® Robotic Arm Interactive Orthopaedic System, which allows surgeons to perform a precise knee resurfacing procedure called MAKOplasty®.

MAKOplasty®, which is commonly performed on patients with early to mid-stage osteoarthritis of the knee, has been successfully employed by orthopaedic surgeons in the U.S. since 2006 to enhance the accuracy of the surgical procedure and significantly improve patient recovery time. This in turn might reduce the length of time patients stay in hospital post-operation which may translate into considerable cost savings for health trusts.

Jim Mather, Minister for Enterprise, Energy and Tourism, said: “Scotland’s reputation for scientific excellence is globally renowned. We produce one per cent of the world’s published research with only 0.1 per cent of the world’s population, and our health science research is at the heart of many advances in medical technology. All of this means there is no better place to pioneer this exciting new partnership.

- more -

“The new MAKO Centre can help revolutionise the way knee joint replacement surgery is carried out in the UK and will further enhance Scotland’s reputation for being at the forefront of turning the latest scientific research into real health benefits for patients. I am delighted to learn about the launch of this important Centre.”

Dr. Maurice R. Ferré, President and Chief Executive Officer of MAKO, said: “As an innovative, U.S. based public medical device company, we intend to gradually introduce our technology in international markets. To begin this process, we chose partners in the UK who could bring together best-in-class clinical and research services.

“We are delighted that Scottish patients will be the first in the UK to benefit from MAKOplasty® – a procedure that is already transforming partial knee orthopaedic interventions in the USA.”

Professor Jim McDonald, Principal of the University of Strathclyde, said: "The creation of the Centre for Surgical Robotics reflects Strathclyde's strategic mission to apply high quality research and enhance our successful links with industry and the NHS to bring benefits to wider society.”

"If successful, the Centre will contribute to improving the functional outcome of knee surgery patients in Glasgow, reducing pain and helping patients recover more quickly. In addition, the technology could reduce the cost to the NHS.”

He added: "The potential for further developments through this new partnership could transform many other aspects of orthopaedic surgery."

Jim Crombie, Director of Surgery & Anaesthetics for NHS Greater Glasgow and Clyde (NHSGGC), said: “This research study has just started and is typical of NHSGGC’s support of cutting edge science. We will be working closely with University of Strathclyde and MAKO Surgical Corp over the coming three years to support full completion.

“The results of this study will be considered as part of our clinical effectiveness processes. NHSGGC recognise the many benefits associated with working with colleagues within our academic institutions and will continue this type of collaboration across many areas of our service provision.”

- more -
MAKO, the University and NHS Scotland will support the first full and independent randomised clinical trial of the MAKO RIO® and will draw on NHS Greater Glasgow and Clyde’s excellence in orthopaedic innovation and joint replacement surgery, as well as the University’s internationally recognised expertise in biomechanical and functional assessment of orthopaedic devices.

Ends
Notes to editors
MAKO Surgical Corp.
MAKO Surgical Corp. is a medical device company that markets both its RIO® Robotic
Arm Interactive Orthopedic system and its proprietary RESTORIS® implants for minimally invasive orthopedic knee procedures.
The MAKO RIO is a surgeon-interactive tactile surgical platform that incorporates a robotic arm and patient-specific visualization technology and prepares the knee joint for the insertion and alignment of MAKO's resurfacing RESTORIS implants through a minimal incision. The FDA-cleared and CE Mark approved RIO system allows surgeons to provide a precise, consistently reproducible tissue-sparing, bone resurfacing procedure called MAKOplasty® to a large, yet underserved patient population suffering from early to mid-stage osteoarthritic knee disease. MAKO has an intellectual property portfolio of more than 250 licensed or owned patents and patent applications relating to the areas of robotics, haptics, computer assisted surgery and implants.
Additional information can be found at www.makosurgical.com.

University of Strathclyde Bioengineering Unit
The Bioengineering Unit at the University of Strathclyde has been at the forefront of the design and evaluation of orthopaedic implants for more than 40 years. It is home to the UK’s only doctoral training centre in medical devices, and the Strathclyde Institute of Medical Devices – a centre to bring together experts in engineering, the life sciences and medicine to create pioneering medical devices and technology to improve patient care. More at www.strath.ac.uk

Forward-Looking Statements
This press release contains forward-looking statements regarding, among other things, statements related to expectations, goals, plans, objectives and future events. MAKO intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Reform Act of 1995. In some cases, forward-looking statements can be identified by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause actual results to differ materially from those indicated by forward-looking statements, many of which are beyond MAKO’s ability to control or predict. Such factors, among others, may have a material adverse effect on MAKO’s business, financial condition and results of operations and may include the potentially significant impact of a continued economic downturn or delayed economic recovery on the ability of MAKO’s customers to secure adequate funding, including access to credit, for the purchase of MAKO’s products or cause MAKO’s customers to delay a purchasing decision, changes in competitive conditions and prices in MAKO’s markets, unanticipated issues relating to intended product launches, decreases in sales of MAKO’s principal product lines, increases in expenditures related to increased or changing governmental regulation or taxation of MAKO’s business, unanticipated issues in securing regulatory clearance or approvals for new products or upgrades or changes to MAKO’s current products, the impact of the recently enacted United States healthcare reform legislation on hospital spending, reimbursement, and the taxing of medical device companies, loss of key management and other personnel or inability to attract such management and other personnel and unanticipated intellectual property expenditures required to develop, market, and defend MAKO’s products. These and other risks are described in greater detail under Item 1A, “Risk Factors,” in MAKO’s annual report on Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarterly period ended March 31, 2010, each as filed with the Securities and Exchange Commission. Given these uncertainties, undue reliance should not be placed on these forward-looking statements. MAKO does not undertake any obligation to release any revisions to these forward-looking statements publicly to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
“MAKOplasty®,” “RESTORIS®,” and “RIO®,” as well as the “MAKO” logo, whether standing alone or in connection with the words “MAKO Surgical Corp.” are trademarks of MAKO Surgical Corp.

Issued by The BIG Partnership
For further information please contact:
Brian McClean
The BIG Partnership
T: 0141 333 9585 / 0775 4390 160

Kat Ferguson
Press Officer
University of Strathclyde
Tel: 0141 548 4123
E: [email protected]

PICTURE CAPTION:
MAKO Surgical Corp, a US medical device firm selects Scotland for landmark clinical study. Dr Maurice Ferré President & Chief Exec of MAKO (left) and Orthopaedic Surgeon Mark Blyth (right) examine the robot during the launch.


Issued by The BIG Partnership
For further information please contact:
Brian McClean
The BIG Partnership
T: 0141 333 9585 / 0775 4390 160

Kat Ferguson
Press Officer
University of Strathclyde
Tel: 0141 548 4123
E: [email protected]

Search by :

Keyword :

Start Date :

End Date :